CME Group Director Acquires 532 Shares at $273.03, Holdings Rise to 3,640

CME Group director Phyllis M. Lockett reported an acquisition of 532 shares of Class A Common Stock on June 25, 2025 at a price of $273.03 per share.

Rhea-AI Filing Summary

CME Group director Phyllis M. Lockett reported an acquisition of 532 shares of Class A Common Stock on June 25, 2025 at a price of $273.03 per share. The shares were granted pursuant to the CME Group Director Stock Plan.

Following this transaction, Lockett now beneficially owns 3,640 shares directly. The filing indicates this was a planned stock grant as part of director compensation rather than an open market purchase.

• Transaction Code: A (Grant/Award)
• Ownership Form: Direct (D)
• Filing Type: Form 4 (Statement of Changes in Beneficial Ownership)
• Total Transaction Value: Approximately $145,252

This insider transaction represents routine director compensation and does not indicate any unusual trading patterns or significant changes in ownership structure.

Insider Trade Summary

Grant/Award: 532 shares

Grant/Award 1 txn

Insider Lockett Phyllis M

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock Class A	532	$273.03	$145K

Holdings After Transaction: Common Stock Class A — 3,640 shares (Direct)

Footnotes (1)

1. F1. Granted pursuant to the CME Group Director Stock Plan, as amended and restated.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many CME Group shares did Director Phyllis Lockett acquire on June 25, 2025?

According to the Form 4 filing, Director Phyllis Lockett acquired 532 shares of CME Group Class A Common Stock on June 25, 2025, at a price of $273.03 per share.

What is Phyllis Lockett's total CME stock ownership after the June 2025 transaction?

Following the reported transaction, Phyllis Lockett beneficially owned 3,640 shares of CME Group Class A Common Stock directly (indicated by 'D' under ownership form).

How were the CME shares granted to Director Lockett in June 2025?

The shares were granted pursuant to the CME Group Director Stock Plan, as amended and restated, as indicated in the footnotes of the Form 4 filing.

Who signed the Form 4 filing for CME Director Phyllis Lockett?

The Form 4 was signed by Jenelle Chalmers on behalf of Phyllis M. Lockett on June 26, 2025.

What is Phyllis Lockett's role at CME Group according to the Form 4?

According to the Form 4 filing, Phyllis M. Lockett serves as a Director of CME Group Inc., as indicated by the 'X' marked under the Director relationship field.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/26/2025 - 06:35 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Lockett Phyllis M

(Last) (First) (Middle)

20 S. WACKER DR.

(Street)

CHICAGO IL 60606

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
CME GROUP INC. [ CME ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
06/25/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock Class A	06/25/2025		A(1)		532	A	$273.03	3,640	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Granted pursuant to the CME Group Director Stock Plan, as amended and restated.

Remarks:

	By: Jenelle Chalmers For: Phyllis M. Lockett	06/26/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.